UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

December 1, 2017: By Joan McKenna

ExonateUK-based Exonate, an early stage company developing an eye drop treatment for wet AMD and diabetic macular edema, has formed a clinical advisory board of five ophthalmic experts.

Exonate’s preclinical compounds are designed to inhibit a protein kinase called SRPK1, which promotes production of vascular endothelial growth factor (VEGF), driving angiogenesis and retinal disease progression.

The five members of the advisory board are:

—Peter Adamson, PhD, head of ophthalmology research and development at Netherlands-based ProQR Therapeutics;

—Lloyd Paul Aiello, MD, PhD, professor of ophthalmology at Harvard Medical School and founding chair of the National Eye Institute Diabetic Retinopathy Clinical Research Network;

—Peter Campochiaro, MD, professor of ophthalmology at the Johns Hopkins Wilmer Eye Institute;

—Usha Chakravarthy, MD, professor of ophthalmology at Queen’s University Belfast, internationally known for research of the molecular mechanisms of AMD and diabetic retinopathy;

—Robyn Guymer, MBBS, PhD, professor of ophthalmology at Melbourne University, deputy director of the Centre for Eye Research Australia, and a senior retinal specialist at the Royal Victorian Eye and Ear Hospital.

In February, Exonate announced it had been awarded a £4.9 million seeding drug discovery award by the Wellcome Trust, a global charitable foundation, to continue development of its retinal candidates.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022